1.Study of re-examination compliance of patients with breast cancer in the stage of recovery
Yixuan LI ; Guizhen WU ; Qingshen LIU ; Chuyu ZHU ; Huiqing YE
Chinese Journal of Primary Medicine and Pharmacy 2008;15(8):1251-1252
Objective To investigate the influencing factors on re-examination compliance of patients with breast cancer Who were in the stage of recovery.Methods By clinic services and telephones,we investigated the reexamination compliance of 189 cases of breast cancer.Results 66.1% of the cases took periodic re-examinations and on the opposite,33.9% of the patients didn't do so.Statistical meaning could be found from the difference of ages,living sites and survival time limits(P<0.05).Conclusions The main factors to influence the re-examination compliance of patients with breast cancer are age,living site and survival time limit.And it is possible to improve the re-examination compliance of patients by enhancing health education,raising medicsl levels and service qualities,and creating comfortable environment for patients.
2.Comparison of the Immunogenicities of HIV-1 Mutants Based on Structural Modification of env
Jianhui NIE ; Chuntao ZHANG ; Huihui CHONG ; Xueling WU ; Chuyu LIU ; Yu WU ; Chenyan ZHAO ; Linqi ZHANG ; Youchun WANG
Virologica Sinica 2008;23(4):233-246
Eleven env mutants were designed and generated by site-directed mutagenesis of the regions around Nab epitopes and deletions of variable regions in env.The immunogenicities of the generated mutants were evaluated using single-cycle infection neutralization assays with two pseudoviruses and IFN-γELISPOT.Overall,five mutants(dWt,M2,M5-2,M5-1 and dM7)induced highed neutralization activities for both pseudoviruses than plasmid Wt,while only two of the mutants(dWt and M5-2)showed significant differences(P<0.05).Two mutants(M2 and dM2)induced more Env-specific T cells than plasmid Wt.Statistically however,significance was only reached for mutant M2.Thus,properly modified HIV-1 Env may have the potential to induce potent cellular and humoral immune responses.